0.4782 USD
-0.15 (-23.37%)
0.4405 USD
-0.04 (-7.88%)
Overall EVFM gets a fundamental rating of 2 out of 10. We evaluated EVFM against 190 industry peers in the Pharmaceuticals industry. The financial health of EVFM is average, but there are quite some concerns on its profitability. While showing a medium growth rate, EVFM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year EVFM has reported negative net income.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -552.28% | ||
| ROE | N/A | ||
| ROIC | 99.62% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -1324.48% | ||
| PM (TTM) | -1676.29% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EVFM is creating value.
- The number of shares outstanding for EVFM has been reduced compared to 1 year ago.
- EVFM has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -55.10, we must say that EVFM is in the distress zone and has some risk of bankruptcy.
- There is no outstanding debt for EVFM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -55.1 |
ROIC/WACC11.33
WACC8.79%
2.3 Liquidity
- EVFM has a Current Ratio of 0.14. This is a bad value and indicates that EVFM is not financially healthy enough and could expect problems in meeting its short term obligations.
- EVFM has a Quick Ratio of 0.14. This is a bad value and indicates that EVFM is not financially healthy enough and could expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.14 | ||
| Quick Ratio | 0.1 |
3. Growth
3.1 Past
- The earnings per share for EVFM have decreased strongly by -553.85% in the last year.
- Looking at the last year, EVFM shows a very strong growth in Revenue. The Revenue has grown by 630.13%.
EPS 1Y (TTM)-553.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-414.29%
Revenue 1Y (TTM)630.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%282.97%
3.2 Future
- EVFM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.45% yearly.
- EVFM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 106.58% yearly.
EPS Next Y57.85%
EPS Next 2Y38.15%
EPS Next 3Y25.03%
EPS Next 5Y13.45%
Revenue Next Year295.01%
Revenue Next 2Y172.93%
Revenue Next 3Y130.74%
Revenue Next 5Y106.58%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- EVFM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVFM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -0.88 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as EVFM's earnings are expected to grow with 25.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.15%
EPS Next 3Y25.03%
5. Dividend
5.1 Amount
- No dividends for EVFM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.4782
-0.15 (-23.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-04 2022-08-04/amc
Earnings (Next)11-14 2022-11-14
Inst Owners0%
Inst Owner Change-99.93%
Ins Owners25.96%
Ins Owner Change0%
Market Cap20.18M
Revenue(TTM)11.39M
Net Income(TTM)-190.93M
Analysts80
Price Target11.27 (2256.75%)
Short Float %0.06%
Short Ratio0
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.77 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | -0.88 |
EPS(TTM)-15.3
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.27
BVpS-2.94
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -552.28% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | 99.62% | ||
| ROICexc | N/A | ||
| ROICexgc | 99.62% | ||
| OM | -1324.48% | ||
| PM (TTM) | -1676.29% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.14 | ||
| Quick Ratio | 0.1 | ||
| Altman-Z | -55.1 |
F-Score4
WACC8.79%
ROIC/WACC11.33
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-553.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-414.29%
EPS Next Y57.85%
EPS Next 2Y38.15%
EPS Next 3Y25.03%
EPS Next 5Y13.45%
Revenue 1Y (TTM)630.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%282.97%
Revenue Next Year295.01%
Revenue Next 2Y172.93%
Revenue Next 3Y130.74%
Revenue Next 5Y106.58%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
EVOFEM BIOSCIENCES INC / EVFM FAQ
Can you provide the ChartMill fundamental rating for EVOFEM BIOSCIENCES INC?
ChartMill assigns a fundamental rating of 2 / 10 to EVFM.
What is the valuation status for EVFM stock?
ChartMill assigns a valuation rating of 0 / 10 to EVOFEM BIOSCIENCES INC (EVFM). This can be considered as Overvalued.
How profitable is EVOFEM BIOSCIENCES INC (EVFM) stock?
EVOFEM BIOSCIENCES INC (EVFM) has a profitability rating of 1 / 10.
Is the dividend of EVOFEM BIOSCIENCES INC sustainable?
The dividend rating of EVOFEM BIOSCIENCES INC (EVFM) is 0 / 10 and the dividend payout ratio is 0%.